Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Survival Rates Following Hepatoma Resection Continues to Improve

By HospiMedica International staff writers
Posted on 16 Mar 2011
Survival after resection of hepatocellular carcinoma (HCC) has improved significantly over the past 20 years, even in patients with advanced disease, according to a new report.

Researchers at Queen Mary Hospital (Hong Kong, China) and the University of Hong Kong (HKU; China; www.hku.hk) investigated the trend of the posthepatectomy survival outcomes of HCC patients by analysis of a prospective cohort of 1,198 patients between 1989 and 2008. More...
The patients were categorized into two 10-year periods: period 1, before 1999 (totaling 390 patients), and period 2, after 1999 (totaling 808 patients). Patients in group 2 were managed according to a modified protocol and technique established in previous years.

The results showed that the patients in group 2 were older and had a higher incidence of comorbid illness and cirrhosis. Despite this, they had a lower hospital mortality rate, longer 5-year overall survival, and higher disease-free survival rates. An improvement in the overall survival rate was observed in patients with cirrhosis, those undergoing major hepatectomy, and those with tumors of tumor-node-metastasis stages II, IIIA, and IVA. A significant increase in the survival rates was also seen in patients whose tumors were considered transplantable. In all, multivariate analysis showed a significantly more favorable patient survival for hepatectomy in period 2. The study was published early online on February 17, 2011, in the Annals of Surgery.

"Further improvement of results depends on technical refinement to reduce blood loss to the minimum, avoid blood transfusion, preserve liver remnant function, secure tumor-free resection margins, and meticulous perioperative care to reduce complications,” said lead author Prof. Sheung Tat Fan, MD, and colleagues of the Laboratory for Liver Research at HKU and Queen Mary Hospital. "Life-long surveillance for recurrence and prompt treatment are mandatory, but development of more effective local ablation methods are needed to lengthen postrecurrence survival.”


Related Links:

Queen Mary Hospital

University of Hong Kong

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Immobilization System
Cranial 4Pi Immobilization
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.